Last reviewed · How we verify
HNC042 single dose — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
HNC042 single dose (HNC042 single dose) — Guangzhou Henovcom Bioscience Co. Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HNC042 single dose TARGET | HNC042 single dose | Guangzhou Henovcom Bioscience Co. Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HNC042 single dose CI watch — RSS
- HNC042 single dose CI watch — Atom
- HNC042 single dose CI watch — JSON
- HNC042 single dose alone — RSS
Cite this brief
Drug Landscape (2026). HNC042 single dose — Competitive Intelligence Brief. https://druglandscape.com/ci/hnc042-single-dose. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab